In the five-year agreement, Medtronic will be the exclusive sales agent for Kuros' product in certain U.S. spine geographies.

Kuros Biosciences USA's strategic, exclusive sales agency agreement with Medtronic could boost adoption of its MagnetOs bone ...

Kuros Biosciences AG / Key word (s): Agreement Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the Medtronic spinal division 07-Jan-2025 / 07:00 CET/CEST Release of an ad ...

From new partnerships to acquisitions, here are four key developments from spine and orthopedic medtech companies since Jan. 1.

Medtronic and Kuros Biosciences signed a strategic agreement to support sales of the MagnetOs bone graft technology.

The remaining part of Kuros Therapeutics continued in a new company named Kuros Biosurgery, which in January 2016 acquired Cytos Biotechnology in a reverse IPO and changed its name to Kuros ...

In a reverse IPO Kuros Biosurgery acquired Cytos Biotechnology in January 2016 and subsequently was renamed Kuros Biosciences. Kuros Biosciences focuses on orthobiologics. As of 2017 the company ...

Medtronic will act as the exclusive sales agent of MagnetOsTM for Kuros Biosciences USA, Inc. in mutually agreed upon sales territories for use in spine surgeriesKuros will work collaboratively to sel ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...